Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients

Pier Luigi Zinzani; Umberto Vitolo; Simonetta Viviani; Paolo Corradini; Giovanna Motta; Monica Tani; Nicola Cascavilla; Stefan Hohaus; Francesco Merli; Lisa Argnani; Alessandro Broccoli

doi:10.1016/j.clml.2015.02.023

Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients

Pier Luigi Zinzani, Umberto Vitolo, Simonetta Viviani, Paolo Corradini, Giovanna Motta, Monica Tani, Nicola Cascavilla, Stefan Hohaus, Francesco Merli, Lisa Argnani, Alessandro Broccoli

Risultato della ricerca: Contributo in rivista › Articolo in rivista › peer review

16 Citazioni (Scopus)

Abstract

The optimal treatment of patients with heavily pretreated Hodgkin's lymphoma is controversial. Brentuximab vedotin is an active single agent in this context. Also, bendamustine can be regarded as a safe and effective alternative for patients with relapse after autologous transplantation and as an interesting cytoreductive strategy before allogeneic transplantation.

Lingua originale	English
pagine (da-a)	404-408
Numero di pagine	5
Rivista	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume	15
DOI	https://doi.org/10.1016/j.clml.2015.02.023
Stato di pubblicazione	Pubblicato - 2015

Keywords

Bendamustine
Brentuximab vedotin
Hodgkin's lymphoma
Refractory
Relapsed

Accesso al documento

10.1016/j.clml.2015.02.023

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Zinzani, P. L., Vitolo, U., Viviani, S., Corradini, P., Motta, G., Tani, M., Cascavilla, N., Hohaus, S., Merli, F., Argnani, L., & Broccoli, A. (2015). Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 15, 404-408. https://doi.org/10.1016/j.clml.2015.02.023

@article{9f6c3470d2bd40a699275a13305609df,

title = "Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients",

abstract = "The optimal treatment of patients with heavily pretreated Hodgkin's lymphoma is controversial. Brentuximab vedotin is an active single agent in this context. Also, bendamustine can be regarded as a safe and effective alternative for patients with relapse after autologous transplantation and as an interesting cytoreductive strategy before allogeneic transplantation.",

keywords = "Bendamustine, Brentuximab vedotin, Hodgkin's lymphoma, Refractory, Relapsed, Bendamustine, Brentuximab vedotin, Hodgkin's lymphoma, Refractory, Relapsed",

author = "Zinzani, {Pier Luigi} and Umberto Vitolo and Simonetta Viviani and Paolo Corradini and Giovanna Motta and Monica Tani and Nicola Cascavilla and Stefan Hohaus and Francesco Merli and Lisa Argnani and Alessandro Broccoli",

year = "2015",

doi = "10.1016/j.clml.2015.02.023",

language = "English",

volume = "15",

pages = "404--408",

journal = "CLINICAL LYMPHOMA MYELOMA & LEUKEMIA",

issn = "2152-2650",

publisher = "DALLAS, USA: CIG MEDIA GROUP, LP",

}

Zinzani, PL, Vitolo, U, Viviani, S, Corradini, P, Motta, G, Tani, M, Cascavilla, N, Hohaus, S, Merli, F, Argnani, L & Broccoli, A 2015, 'Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients', CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 15, pagg. 404-408. https://doi.org/10.1016/j.clml.2015.02.023

Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients. / Zinzani, Pier Luigi; Vitolo, Umberto; Viviani, Simonetta et al.
In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Vol. 15, 2015, pag. 404-408.

Risultato della ricerca: Contributo in rivista › Articolo in rivista › peer review

TY - JOUR

T1 - Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients

AU - Zinzani, Pier Luigi

AU - Vitolo, Umberto

AU - Viviani, Simonetta

AU - Corradini, Paolo

AU - Motta, Giovanna

AU - Tani, Monica

AU - Cascavilla, Nicola

AU - Hohaus, Stefan

AU - Merli, Francesco

AU - Argnani, Lisa

AU - Broccoli, Alessandro

PY - 2015

Y1 - 2015

N2 - The optimal treatment of patients with heavily pretreated Hodgkin's lymphoma is controversial. Brentuximab vedotin is an active single agent in this context. Also, bendamustine can be regarded as a safe and effective alternative for patients with relapse after autologous transplantation and as an interesting cytoreductive strategy before allogeneic transplantation.

AB - The optimal treatment of patients with heavily pretreated Hodgkin's lymphoma is controversial. Brentuximab vedotin is an active single agent in this context. Also, bendamustine can be regarded as a safe and effective alternative for patients with relapse after autologous transplantation and as an interesting cytoreductive strategy before allogeneic transplantation.

KW - Bendamustine

KW - Brentuximab vedotin

KW - Hodgkin's lymphoma

KW - Refractory

KW - Relapsed

KW - Bendamustine

KW - Brentuximab vedotin

KW - Hodgkin's lymphoma

KW - Refractory

KW - Relapsed

UR - http://hdl.handle.net/10807/113294

U2 - 10.1016/j.clml.2015.02.023

DO - 10.1016/j.clml.2015.02.023

M3 - Article

SN - 2152-2650

VL - 15

SP - 404

EP - 408

JO - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

JF - CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

ER -

Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo